Dope CFO

Item 7 investment costs suit a services play, emphasizing low-overhead home operations over expensive builds, though exact ranges demand FDD scrutiny for training, marketing, and setup expenses. Ongoing fees per Item 6 include royalties and fund contributions typical for business services, but the glaring gap is no Item 19 disclosure—meaning no average gross sales, expenses, or EBITDA benchmarks from existing units. This matters deeply in a specialized field like cannabis finance, where client acquisition hinges on industry expertise amid regulatory flux; without validated performance, projections rest on franchisee hustle in an unproven system.

System health per Item 20 reflects its infancy: just 6 franchise locations plus 1 corporate since 2022, with 6 new units projected—a 100% growth target hinting at franchisor optimism. No data on terminations, transfers, or renewals suggests stability so far, but the tiny base amplifies any hiccups. For investors, this spells high-upside potential in a $30B+ cannabis market needing compliant accounting, but demands caution—low unit count means sparse peer validation, making it a bet on the niche's expansion more than established cash flow.